Resistant hypertension and associated comorbidities in a veterans affairs population

Journal of Clinical Hypertension

Volumn 16, Issue 10, 2014, Pages 741-745

  Acharya, Tushar ^a,b   Tringali, Steven ^a,b   Singh, Manmeet ^a,b   Huang, Jian ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGED; ARTICLE; BODY MASS; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; ERECTILE DYSFUNCTION; FRAMINGHAM RISK SCORE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RESISTANT HYPERTENSION; TRANSIENT ISCHEMIC ATTACK; VETERAN; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; FEMALE; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTOR; STATISTICAL MODEL; STATISTICS; UNITED STATES; VERY ELDERLY;

ANTIHYPERTENSIVE AGENT;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BODY MASS INDEX; CALIFORNIA; CARDIOVASCULAR DISEASES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE; FEMALE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; STATISTICS AS TOPIC; VETERANS;

EID: 84907818275     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12410     Document Type: Article

References (32)

1. Williams B. Hypertension and the "J-curve." J Am Coll Cardiol. 2009;54:1835-1836.
2. World Health Organization. Global status report on noncommunicable diseases 2010-Description of the global burden of NCDs, their risk factors and determinants. http://www.who.int/nmh/publications/ncd_report2010/en/. Published April 2011. Accessed September 3, 2014.
3. Egan BM, Zhao Y, Axon R. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043-2050.
4. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association professional education committee of the council for high blood pressure research. Hypertension. 2008;51:1403-1419.
5. Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure. Factors associated with lack of blood pressure control in the community. Hypertension. 2000;36:594-599.
6. Cushman WC, Ford CE, Cutler JA, et al; for the ALLHAT Collaborative research group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwith). 2002;4:393-404.
7. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150:776-783.
8. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076-1080.
9. Kaplan NM. Resistant hypertension. J Hypertens. 2005;23:1441-1444.
10. Garg JP, Elliott WJ, Folker A, et al. Resistant hypertension revisited: a comparison of two university based cohorts. Am J Hypertens. 2005;18:619e26.
11. Leotta G, Rabbia F, Canade A, et al. Characteristics of the patients referred to a hypertension unit between 1989 and 2003. J Hum Hypertens. 2008;22:119e21.
12. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation. 2012;125:1594-1596.
13. U.S. Census Bureau, American Community Survey, PUMS 2009.
14. Bramlage P, Pittrow D, Wittchen H-U, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17:904-910.
15. Nishizaka MK, Pratt-Ubunama M, Zaman MA, et al. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005;18:805-812.
16. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41:625-633.
17. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180-187.
18. Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988-2008. Circulation. 2011;124:1046-1058.
19. Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001;161:2661-2667.
20. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245-1250.
21. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635-1642.
22. Kumbhani DJ, Steg PG, Cannon CP, et al; on behalf of the REACH Registry Investigators. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013;34:1204-1214.
23. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877-884.
24. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2001;161:1207-1216.
25. Saelen MG, Prøsch LK, Gudmundsdottir H, et al. Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function. Blood Press. 2005;14:170-176.
26. Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002;143:961-965.
27. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110:738-743.
28. Nunes KP, Labazi H, Webb RC. New insights into hypertension-associated erectile dysfunction. Curr Opin Nephrol Hypertens. 2012;21:163-170.
29. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol. 2004;171:2341-2345.
30. Cordero A, Bertomeu-Martínez V, Mazón P, et al. Erectile dysfunction may improve by blood pressure control in patients with high-risk hypertension. Postgrad Med. 2010;122:51-56.
31. Grassi G, Facchini A, Trevano FQ, et al. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension. 2005;46:321-325.
32. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19:2271-2277.